Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

NCT03591146 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Inguinal Hernia

Interventions

DRUG: TLC590
DRUG: Naropin

Sponsor

Taiwan Liposome Company